Analysts Anticipate Nuvectra Corporation (NVTR) to Post -$1.15 Earnings Per Share
Equities research analysts predict that Nuvectra Corporation (NASDAQ:NVTR) will announce ($1.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Nuvectra’s earnings. Nuvectra reported earnings per share of ($1.27) during the same quarter last year, which indicates a positive year over year growth rate of 9.4%. The firm is scheduled to report its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Nuvectra will report full-year earnings of ($4.58) per share for the current financial year. For the next financial year, analysts forecast that the business will post earnings of ($3.73) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Nuvectra.
Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.07. The firm had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. The company’s revenue for the quarter was up 100.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.92) earnings per share.
A number of hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its position in Nuvectra by 4.0% during the third quarter. Dimensional Fund Advisors LP now owns 730,117 shares of the company’s stock valued at $9,681,000 after purchasing an additional 28,268 shares during the last quarter. FNY Partners Fund LP raised its stake in shares of Nuvectra by 449.6% in the third quarter. FNY Partners Fund LP now owns 13,740 shares of the company’s stock valued at $182,000 after acquiring an additional 11,240 shares during the period. Gilder Gagnon Howe & Co. LLC raised its stake in shares of Nuvectra by 4.5% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 996,557 shares of the company’s stock valued at $13,214,000 after acquiring an additional 43,126 shares during the period. Group One Trading L.P. purchased a new stake in shares of Nuvectra in the second quarter valued at $167,000. Finally, Wolverine Trading LLC purchased a new stake in shares of Nuvectra in the second quarter valued at $156,000. Institutional investors and hedge funds own 58.89% of the company’s stock.
Shares of Nuvectra (NASDAQ NVTR) traded down $0.24 during midday trading on Wednesday, hitting $7.76. 55,406 shares of the stock were exchanged, compared to its average volume of 52,580. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $86.27, a PE ratio of -1.65 and a beta of -0.91. Nuvectra has a 1 year low of $4.90 and a 1 year high of $15.00.
TRADEMARK VIOLATION WARNING: “Analysts Anticipate Nuvectra Corporation (NVTR) to Post -$1.15 Earnings Per Share” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/30/analysts-anticipate-nuvectra-corporation-nvtr-to-post-1-15-earnings-per-share.html.
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related stocks with our FREE daily email newsletter.